Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Mycoplasma vaccines and uses thereof

Inactive Publication Date: 2019-01-31
UNIVERSITY OF SASKATCHEWAN +2
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent is about a new treatment for a common infection in humans and animals calledMycoplasma. The treatment can help reduce the prevalence of this infection and provide safer and more effective vaccines. This technology can be used to treat or prevent variousMycoplasma infections, including CBPP.

Problems solved by technology

Mycoplasma diseases cause serious illness in humans and other animals and also result in severe economic losses to the food industry.
Currently, the disease is a major constraint to cattle production in Africa causing severe socio-economic consequences.
This strategy, however, does not prove realistic in some countries where it is considered too costly and logistically difficult to apply.
Stamping-out is also problematic because CBPP occurs among pastoral communities where movement control is difficult to implement.
However, a combination of five variable surface proteins from Mmm did not provide protection against CBPP (Hamsten et al., Clinical and Vaccine Immunology (2010) 17:853-86).
However, the use of Mycoplasma proteins and nucleic acids as described herein in vaccine compositions has not heretofore been suggested.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mycoplasma vaccines and uses thereof
  • Mycoplasma vaccines and uses thereof
  • Mycoplasma vaccines and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Analysis of Immune Responses to Recombinant Proteins from Mycoplasma mycoides

1.1 Materials and Methods

[0204]Identification of M. mycoides Protein Antigens

[0205]The complete genome sequences of M. mycoides subsp. mycoides PG1 (Accession number BX293980, Westberg et al., Genome Res. (2004) 14:221-227); Gladysdale (Accession number CP002107, Wise et al., J Bacteriol. (2012) 194:4448-4449); and partial sequences of strains IS22, 138 / 5, 9809 (Accession numbers JQ307942 to JQ308103, Churchward et al., Vet Microbiol. (2012) 159:257-259; and 8676 / 93 (Accession number AJ515918.1, Botehlo et al. direct submission) were obtained from the NCBI Genome database for analysis.

[0206]A reverse-vaccinology pipeline was assembled and applied for M. mycoides antigen prediction. PSORTb 3.0 was used to identify non-cytoplasmic proteins, including extracellular, transmembrane and unknown-location ones (Yu et al., Nucleic Acids Res. (2011) 39:D241-244; Yu et al., Bioinformatics (2010) 26:1608-1615). The tr...

example 2

Protective Immune Responses to Recombinant Proteins from M. mycoides Against CBPP

2.1 Materials and Methods

[0239]M. mycoides Protein Antigens, Vaccines and Administration

[0240]M. mycoides protein antigens were identified, ranked and produced as described in Example 1. Cattle were grouped and vaccines were prepared and administered to cattle as described above. As explained, three challenge trials (comprising 60 cattle each for trials 1 and 2 and 50 for trial 3) were conducted, with each trial having vaccinated groups of 10 cattle each and a placebo group as indicated in Table 1. Each group of animals was immunized with a pool of five proteins as described above.

[0241]Mmm Strain and Growth Conditions

[0242]The Mmm Afade strain was grown in Gourlay's medium (Gourlay, R. N, Research in Veterinary Science (1964) 5:473-482) containing 20% heat-inactivated pig serum, 0.25 mg penicillin / ml, 0.025% thallous acetate. The medium was stored at 4° C. and used within 14 days.

[0243]For the culture ...

example 3

Production of M. mycoides Antigen Fusions and Conjugates with Leukotoxin Carrier Protein

[0279]The M. mycoides genes used in the fusions and LtxA conjugates were codon-optimized for E. coli expression, synthesized and cloned, as described above. For fusions, the genes were designed such that the resulting fusion protein included amino acid linkers between the two proteins. Fusions constructed included YP_004400127.1-YP_004399790.1; YP_004400610.1-YP_004400580.1; MSC_0446-MSC_0117; and MSC_0922-MSC_1058. As shown in the Figures, the YP_004400127.1-YP_004399790.1 fusion includes a Gly6 amino acid linker between the YP_004400127.1 and YP_004399790.1 proteins (see, FIGS. 25B and 27B); the YP_004400610.1-YP_004400580.1 fusion includes a Gly5 linker between the two proteins (see, FIGS. 26B and 28B); the MSC_0446-MSC_0117 fusion includes a Gly3 linker between the proteins (See FIG. 37B); and the MSC_0922-MSC_1058 fusion includes a Gly3 linker between the proteins (See FIG. 38B).

[0280]To pro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

Immunogenic proteins comprising Mycoplasma mycoides subsp. mycoides and M. mycoides subsp. capri proteins, encoding polynucleotides, a method for producing said proteins, and use of compositions to prevent M. mycoides subsp. mycoides infections are disclosed.

Description

TECHNICAL FIELD[0001]The present invention pertains generally to immunogenic compositions and methods for treating and / or preventing Mycoplasma infection. In particular, the invention relates to the use of multiple Mycoplasma antigens in subunit vaccine compositions to elicit immune responses against Mycoplasma infections such as contagious bovine pleuropneumonia.BACKGROUND[0002]Mycoplasma, belonging to the class Mollicutes, is a bacterium that lacks a cell wall and causes a number of diseases in humans, livestock, domestic animals and birds. Mycoplasma diseases cause serious illness in humans and other animals and also result in severe economic losses to the food industry.[0003]For example, contagious bovine pleuropneumonia (CBPP) is a highly communicable lung disease in cattle caused by Mycoplasma mycoides subsp. mycoides (Mmm), previously specified as biotype small colony (Mmm SC) (Manso-Silvan et al., International Journal of Systematic and Evolutionary Microbiology (2009) 59:13...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/02A61P31/04C07K14/30C12N15/62
CPCA61K39/0241A61P31/04C07K14/30C12N15/62A61K2039/55516A61K2039/55561A61K2039/55566C07K2319/00
Inventor POTTER, ANDREWGERDTS, VOLKERPEREZ-CASAL, JOSEWANG, YEJUNWESONGA, HEZRONSOI, REUBENNAESSENS, JANJORES, JOERG
Owner UNIVERSITY OF SASKATCHEWAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com